EHC Quote, Financials, Valuation and Earnings

Elite Health Systems, Inc. has a net margin of 13.07% compared to Encompass Health Corp.'s net margin of --. Encompass Health Corp.'s return on equity of 24.73% beat Elite Health Systems, Inc.'s return on equity of -72.99%.

Encompass Health Corp. has a consensus price target of $142.73, signalling upside risk potential of 31%. On the other hand Elite Health Systems, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Encompass Health Corp. has higher upside potential than Elite Health Systems, Inc., analysts believe Encompass Health Corp. is more attractive than Elite Health Systems, Inc..

Encompass Health Corp. has a beta of 0.727, which suggesting that the stock is 27.328% less volatile than S&P 500. In comparison Elite Health Systems, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.465%.

Encompass Health Corp. has a quarterly dividend of $0.19 per share corresponding to a yield of 0.66%. Elite Health Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health Corp. pays 13% of its earnings as a dividend. Elite Health Systems, Inc. pays out -- of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health Corp. quarterly revenues are $1.5B, which are larger than Elite Health Systems, Inc. quarterly revenues of --. Encompass Health Corp.'s net income of $201.9M is higher than Elite Health Systems, Inc.'s net income of -$1.2M. Notably, Encompass Health Corp.'s price-to-earnings ratio is 19.66x while Elite Health Systems, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health Corp. is 1.88x versus 7.08x for Elite Health Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

HCA Healthcare, Inc. has a net margin of 13.07% compared to Encompass Health Corp.'s net margin of 11.09%. Encompass Health Corp.'s return on equity of 24.73% beat HCA Healthcare, Inc.'s return on equity of 3428.29%.

Encompass Health Corp. has a consensus price target of $142.73, signalling upside risk potential of 31%. On the other hand HCA Healthcare, Inc. has an analysts' consensus of $541.52 which suggests that it could fall by -0.53%. Given that Encompass Health Corp. has higher upside potential than HCA Healthcare, Inc., analysts believe Encompass Health Corp. is more attractive than HCA Healthcare, Inc..

Encompass Health Corp. has a beta of 0.727, which suggesting that the stock is 27.328% less volatile than S&P 500. In comparison HCA Healthcare, Inc. has a beta of 1.344, suggesting its more volatile than the S&P 500 by 34.373%.

Encompass Health Corp. has a quarterly dividend of $0.19 per share corresponding to a yield of 0.66%. HCA Healthcare, Inc. offers a yield of 0.53% to investors and pays a quarterly dividend of $0.72 per share. Encompass Health Corp. pays 13% of its earnings as a dividend. HCA Healthcare, Inc. pays out 10.17% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health Corp. quarterly revenues are $1.5B, which are smaller than HCA Healthcare, Inc. quarterly revenues of $19.5B. Encompass Health Corp.'s net income of $201.9M is lower than HCA Healthcare, Inc.'s net income of $2.2B. Notably, Encompass Health Corp.'s price-to-earnings ratio is 19.66x while HCA Healthcare, Inc.'s PE ratio is 19.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health Corp. is 1.88x versus 1.73x for HCA Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group, Inc. has a net margin of 13.07% compared to Encompass Health Corp.'s net margin of 6.82%. Encompass Health Corp.'s return on equity of 24.73% beat Pediatrix Medical Group, Inc.'s return on equity of 19.95%.

Encompass Health Corp. has a consensus price target of $142.73, signalling upside risk potential of 31%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $21.33 which suggests that it could grow by 7.31%. Given that Encompass Health Corp. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe Encompass Health Corp. is more attractive than Pediatrix Medical Group, Inc..

Encompass Health Corp. has a beta of 0.727, which suggesting that the stock is 27.328% less volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.786, suggesting its less volatile than the S&P 500 by 21.358%.

Encompass Health Corp. has a quarterly dividend of $0.19 per share corresponding to a yield of 0.66%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Encompass Health Corp. pays 13% of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Encompass Health Corp. quarterly revenues are $1.5B, which are larger than Pediatrix Medical Group, Inc. quarterly revenues of $493.8M. Encompass Health Corp.'s net income of $201.9M is higher than Pediatrix Medical Group, Inc.'s net income of $33.7M. Notably, Encompass Health Corp.'s price-to-earnings ratio is 19.66x while Pediatrix Medical Group, Inc.'s PE ratio is 10.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health Corp. is 1.88x versus 0.89x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

U.S. Physical Therapy, Inc. has a net margin of 13.07% compared to Encompass Health Corp.'s net margin of 6.45%. Encompass Health Corp.'s return on equity of 24.73% beat U.S. Physical Therapy, Inc.'s return on equity of 8.4%.

Encompass Health Corp. has a consensus price target of $142.73, signalling upside risk potential of 31%. On the other hand U.S. Physical Therapy, Inc. has an analysts' consensus of $105.33 which suggests that it could grow by 26.53%. Given that Encompass Health Corp. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe Encompass Health Corp. is more attractive than U.S. Physical Therapy, Inc..

Encompass Health Corp. has a beta of 0.727, which suggesting that the stock is 27.328% less volatile than S&P 500. In comparison U.S. Physical Therapy, Inc. has a beta of 1.301, suggesting its more volatile than the S&P 500 by 30.094%.

Encompass Health Corp. has a quarterly dividend of $0.19 per share corresponding to a yield of 0.66%. U.S. Physical Therapy, Inc. offers a yield of 2.16% to investors and pays a quarterly dividend of $0.45 per share. Encompass Health Corp. pays 13% of its earnings as a dividend. U.S. Physical Therapy, Inc. pays out 126.62% of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but U.S. Physical Therapy, Inc.'s is not.

Encompass Health Corp. quarterly revenues are $1.5B, which are larger than U.S. Physical Therapy, Inc. quarterly revenues of $202.7M. Encompass Health Corp.'s net income of $201.9M is higher than U.S. Physical Therapy, Inc.'s net income of $13.1M. Notably, Encompass Health Corp.'s price-to-earnings ratio is 19.66x while U.S. Physical Therapy, Inc.'s PE ratio is 58.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Encompass Health Corp. is 1.88x versus 1.62x for U.S. Physical Therapy, Inc.. Usually stocks with elevated PS ratios are considered overvalued.